Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

iganidipine

Known as: 3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
The medical treatment of glaucoma has undergone significant development in recent years. Research in this field is focused on… Expand
2009
2009
espanolEl tratamiento medico del glaucoma ha presentado una gran evolucion en los ultimos anos. Las investigaciones que se estan… Expand
  • table I
2006
2006
The purpose of this study was to determine whether iganidipine, nimodipine and lomerizine, potentially useful calcium channel… Expand
2004
2004
Purpose. To evaluate the effects of topically administered iganidipine hydrochloride, a novel water-soluble Ca2+-channel blocker… Expand
2003
2003
PURPOSE To evaluate the potential of topical iganidipine ophthalmic solution to exert Ca(2+)-antagonistic activity in the… Expand
2002
2002
We evaluated the role of topical iganidipine on experimental aqueous flare elevation in rabbits. Transcorneal diffusion of… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
2001
2001
PURPOSE To study the effect of topically applied iganidipine dihydrochloride (iganidipine), a novel water-soluble calcium channel… Expand
2000
2000
PURPOSE We studied the effect of topically applied iganidipine dihydrochloride, a novel water-soluble calcium channel blocker on… Expand
2000
2000
PURPOSE To investigate the effect of topical iganidipine, a new dihydropyridine derivative calcium channel blocker, on impairment… Expand
1997
1997
Iganidipine, a new water-soluble calcium antagonist, was administered at a nonhypotensive dose (NHD) of 0.3 mg/kg/day, a moderate… Expand